VA
ZURA icon

Verdad Advisers’s Zura Bio ZURA Stock Holding History

Verdad Advisers’s Portfolio ZURA Stock Details ZURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$578K Buy
+97,102
New +$587K 0.65% 51

Other funds holding ZURA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Verdad Advisers's ZURA Position: Q1 2026 in Review

Verdad Advisers opened a new position in Zura Bio (ZURA) in Q1 2026: 97,102 shares worth $578K. The stake represents 0.65% of the portfolio and ranks #51 among its holdings.

94 funds tracked by Wall St. Rank hold ZURA as of Q1 2026.

  • Verdad Advisers held 97,102 shares of Zura Bio worth $578K as of Q1 2026.
  • Zura Bio was a new Verdad Advisers position in Q1 2026.
  • Zura Bio made up 0.65% of Verdad Advisers's portfolio in Q1 2026, its #51 holding.
  • 94 funds tracked by Wall St. Rank held Zura Bio as of Q1 2026.

Based on Verdad Advisers's 13F filing for Q1 2026, filed 15 May 2026.